

REMARKS

Claims 1 to 22 and 25 are pending. Claims 23 and 24 have been cancelled without prejudice. Applicants reserve the right to prosecute any non-elected or cancelled subject matter in future continuation or divisional applications.

Claims 1-25 have been rejected under 35 U.S.C. § 112, first paragraph, because the specification, while allegedly being enabling for making pharmaceutically acceptable salts, allegedly does not reasonably provide enablement for making solvates. Solely to advance prosecution Applicants have amended the claims to remove the term "solvates". Since solvates are a form of species of the presently claimed compounds and salts, the present claims nonetheless encompass such forms. Applicants request that the rejection be withdrawn.

Claims 22-25 have been rejected under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for treatment of breast carcinoma, does not reasonably provide enablement for treating any or all cell proliferative diseases. While Applicants disagree with the Office, solely to advance prosecution, Applicants have amended the claims to focus on that embodiment related to the treatment of breast cancer. Applicants request that the rejection be withdrawn.

CONCLUSION


In view of the foregoing amendments and remarks, Applicants respectfully requests reconsideration and reexamination of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Date: February 15, 2007

By: 
Lauren L. Stevens
Reg. No. 36,691

Tel: (650) 849-6614
Email: lauren.stevens@finnegan.com